Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InoviqASX:IIQ 27 FCF Margin % is -963.91% as of Dec. 2025. GuruFocus rates ASX:IIQ with a GF Score™ of 27/100 and a GF Value™ of A$0.51 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Inoviq ranks worse than 94.09% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Inoviq's Free Cash Flow for the
six
months ended in Dec. 2025 was A$-2.22 Mil. Inoviq's Revenue for the
six
months ended in Dec. 2025 was A$0.23 Mil. Therefore, Inoviq's FCF Margin % for the quarter that ended in Dec. 2025 was -963.91%.
The historical rank and industry rank for Inoviq's FCF Margin % or its related term are showing as below:
ASX:IIQ'
s FCF Margin % Range Over the Past 10 Years
Min: -2336.82 Med: -1291.88 Max: -840.56
Current: -891.75
During the past 13 years, the highest FCF Margin % of Inoviq was -840.56%. The lowest was -2336.82%. And the median was -1291.88%.
ASX:IIQ's FCF Margin % is ranked worse than 94.09% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.8
vs ASX:IIQ: -891.75
Inoviq FCF Margin % Related Terms
Inoviq FCF Margin % Historical Data
* Premium members only.
The historical data trend for Inoviq's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IIQ vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Inoviq's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inoviq FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inoviq's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Inoviq's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inoviq (ASX:IIQ) has a FCF Margin % of -963.91% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Inoviq and its competitors. According to the industry distribution chart, Inoviq ranks #191 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 94.1%.
Is Inoviq's FCF Margin % too high?
Inoviq's current FCF Margin % is -963.91%. Based on the distribution chart, Inoviq ranks #191 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Inoviq has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inoviq's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Inoviq ranks #191 out of 203 companies for FCF Margin %. This places Inoviq in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Inoviq and its competitors. Inoviq's current FCF Margin % is -963.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inoviq stock overvalued right now?
Based on GuruFocus' analysis, Inoviq (ASX:IIQ) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.51, compared to a current price of A$0.20 — trading 60.8% below its estimated fair value. The current FCF Margin % is -963.91%. Inoviq's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Inoviq (ASX:IIQ), the current FCF Margin % is -963.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inoviq (ASX:IIQ) Overvalued in 2026?
Based on GuruFocus' analysis, Inoviq stock appears to be undervalued.
The current stock price of A$0.20 is trading 60.8% below its estimated GF Value™ of A$0.51.
GuruFocus considers Inoviq to be Possible Value Trap.
Key valuation signals for ASX:IIQ:
FCF Margin %: -963.91%
GF Value™: A$0.51 vs. price of A$0.20 (60.8% below fair value)
No single metric tells the full story. See the ASX:IIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
27GF Score
Get the complete analysis for ASX:IIQ
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IIQ has been successfully added to your 
